


c-Myc

Myc

HDAC Inhibitor:
Vorinostat (SAHA)



HDAC (Histone deacetylase)


c-Myc is the master transcription factor for cell proliferation and is involved in numerous hematological and solid cancers.

Proto-oncogene c-Myc, encoding one of the most important transcription factors, plays a pivotal role in tumor initiation and progression. c-Myc regulates hundreds of disparate target genes that participate numerous biological effects, such as cell proliferation, apoptosis, differentiation, and stem cell self-renewal. c-Myc is one of the four factors used in reprogramming somatic cells to induce pluripotent stem (iPS) cells and is implicated in maintaining cancer stem-like cells (CSCs).

The transcription factor c-Myc is a key mediator of the Notch signaling-regulated T cell differentiation. In a well-established in vitro differentiation model of T lymphocytes from hematopoietic stem cells, Notch1 and 4 directly promotes c-Myc expression; dominant-negative (DN) c-Myc inhibits early T cell differentiation. Moreover, the c-Myc expression activated by Notch signaling increases the expression of survivin, an inhibitor of apoptosis (IAP) protein.

c-Myc gene, as a transcription factor of hTERT, is over expressed in a variety of tumors. c-Myc and hTERT expression in local recurrent gastric cancer tissues is much higher than in primary gastric cancer tissues at the protein and mRNA levels.

c-Myc Inhibitors & Modulators

<p>10058-F4</p> <p style="text-align: right;">Cat. No.: HY-12702</p>	<p>10074-G5</p> <p style="text-align: right;">Cat. No.: HY-100996</p>
<p>Bioactivity: 10058-F4 is a c-Myc inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.</p> <p>Purity: 99.92%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>Bioactivity: 10074-G5 is an inhibitor of c-Myc-Max dimerization with an IC₅₀ of 146 μM.</p> <p>Purity: 97.07%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>IZCZ-3</p> <p style="text-align: right;">Cat. No.: HY-111411</p>	<p>KJ Pyr 9</p> <p style="text-align: right;">Cat. No.: HY-19735</p>
<p>Bioactivity: IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size:</p> 	<p>Bioactivity: KJ Pyr 9 is an inhibitor of MYC with a K_d of 6.5 nM in in vitro assay.</p> <p>Purity: 99.25%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>KSI-3716</p> <p style="text-align: right;">Cat. No.: HY-12703</p>	<p>ML327</p> <p style="text-align: right;">Cat. No.: HY-103038</p>
<p>Bioactivity: KSI-3716 is a c-Myc inhibitor.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 250 mg, 500 mg</p> 	<p>Bioactivity: ML327 is a blocker of MYC which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).</p> <p>Purity: 98.04%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>Mycro 3</p> <p style="text-align: right;">Cat. No.: HY-100669</p>	
<p>Bioactivity: Mycro 3 is potent and selective for c-Myc in whole cell assays.</p> <p>Purity: 98.63%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	